Here is a review of glucagon-like peptide-1 receptor agonist use in people with HIV.
|Articles|November 5, 2019
FDA Authorizes Marketing of an HIV-1 Drug Resistance Test
Author(s)Contagion® Editorial Staff
The FDA has authorized marketing of the Sentosa SQ HIV Genotyping Assay, which detects HIV-1 mutations in patients undergoing or about to initiate antiviral treatment.
Advertisement
The US Food and Drug Administration (FDA)
The Sentosa SQ HIV-1 Genotyping Assay detects drug resistance mutations in patients who are undergoing or about to undergo antiviral therapy. The assay detects mutations in the genetics of HIV in a sample of blood using next-generation sequencing.
The FDA examined data from performance studies demonstrating a greater than 95% sensitivity and specificity in detecting 342 drug resistance mutations. This led to the conclusion that the assay provides reasonable assurance of safety and effectiveness for its intended use.
The FDA noted in its statement on the authorization that the assay is not intended for diagnosing infection with HIV. It was also emphasized that the results of the test should be used in combination with clinical observation, patient history, and accompanying laboratory evidence when making patient management decisions.
The assay was evaluated through the de novo premarket review pathway, a regulatory pathway the FDA employs for devices of a new type. The FDA is establishing special controls, which are requirements that test developers must meet with respect to accuracy, reliability, and effectiveness for tests intended to identify HIV mutations. The FDA’s decision creates an entirely new regulatory classification in which subsequent devices of the same type will be classified within.
“Today’s authorization can help health care providers better tailor drug treatment for patients who are beginning antiviral therapy and also for those who have developed resistance to HIV drugs by helping to identify mutations in the HIV-1 virus that can impact the effectiveness of certain drugs,” Peter Marks, MD, PhD, director of the FDA’s Center for Biologics Evaluation and Research said in the FDA’s statement.
Advertisement
Related to this article
In the third episode of the series with Perry N. Halkitis, PhD, MS, MPH, he discusses how human behavior as well as other factors play a significant role in repeating outbreaks.
In the second episode of the series with Perry N. Halkitis, PhD, MS, MPH, he brings his personal experience to this topic and questions whether there should be a shift in who manages the primary care needs of these patients.
New gyrA testing guides ciprofloxacin use for gonorrhea, cutting ceftriaxone reliance while tackling resistance, access, and FDA hurdles.
The federal agency gave the nod for the smallest once-daily single tablet regimen available for virologically suppressed adults with HIV, including those on complex regimens. The approval is based on the results of the 2 phase 3 ARTISTRY trials.
The federal agency gave the nod to dolutegravir (Tivicay PD), making it the first second-generation integrase inhibitor cleared for children with HIV weighing at least 2 kg, including eligible newborns.
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.